Oncoinvent invites for Q3 2025 company update in English on Tuesday 4[th] of November at 08:30 AM CEST. The presentation will be broadcasted live on https://channel.royalcast.com/landingpage/hegnarmedia/20251104_9/. There will be a possibility for Q&A.

Oslo, 3 November 2025: Reference is made to the stock exchange announcement published by Oncoinvent ASA (the “Company”) on 29 October 2025 regarding the completion of the merger between the Company and the former Oncoinvent ASA (reg. no. 995 764 458) (“Oncoinvent”) (the “Merger”).

Oncoinvent ASA (OSE: ONCIN) today announces the appointment of Dr. Ramzi Amri, M.D., Ph.D. as Chief Financial Officer (CFO), effective on or around 15 January. 

Oslo, 29 October 2025 – Reference is made to the previous stock exchange announcements made in connection with the combination of BerGenBio ASA and Oncoinvent ASA (“Oncoinvent”) through a statutory triangular merger (the “Merger”), including the announcements made on 4 August 2025 regarding approval of the Merger by the extraordinary general meetings of the two companies. Reference is further made to the stock exchange announcement made on 24 October 2025 regarding key dates for completion of the Merger and the stock exchange announcement made on 28 October 2025 regarding the approval and publication of the prospectus (the “Prospectus”) prepared in connection with the Merger and the contemplated rights issue in the combined company.

Oncoinvent ASA, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced the presentation of the previously reported final 18-months safety and efficacy results from its Phase 1/2a clinical trial (RAD-18-002) evaluating Radspherin® in patients with peritoneal metastases from colorectal cancer at the 15th PSOGI International Congress on Peritoneal Surface Malignancies, to be held at the Fira Barcelona October 29-31, 2025. Radspherin®, direct intraperitoneal targeting with the alpha-emitter radium-224, aims to eliminate post-surgery micro-metastases and thereby prevent or delay peritoneal recurrence.

Reference is made to the joint stock exchange announcement made on 24 October 2025 by BerGenBio ASA and Oncoinvent ASA (“Oncoinvent”) regarding key dates for completion of the combination of the two companies through a statutory triangular merger (the “Merger”). Reference is further made to the stock exchange announcement made on 28 October 2025 regarding the approval and publication of the prospectus (the “Prospectus”) prepared in connection with the Merger and the contemplated rights issue in the combined company.

Bergen, Norway and Oslo, Norway, 24 October 2025 – Reference is made to the joint stock exchange announcement on 30 June 2025 by BerGenBio ASA (OSE: BGBIO) (“BerGenBio”) and Oncoinvent ASA (OSE: ONCIN) (“Oncoinvent”) regarding the combination of the two companies through a statutory triangular merger (the “Merger”), and the announcements on 4 August 2025 regarding the approval of the merger plan by the extraordinary general meetings of BerGenBio and Oncoinvent, respectively.

New Data Highlight Continued Potential of Radspherin to Prevent Disease Progression Oncoinvent ASA, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced positive final 24-month follow-up results from its Phase 1 clinical trial (RAD-18-001) evaluating Radspherin® in patients with platinum-sensitive recurrent ovarian cancer and peritoneal carcinomatosis. Radspherin®, direct intraperitoneal targeting with the alpha-emitter radium-224, aims to eliminate post-surgery micro-metastases and thereby prevent or delay peritoneal recurrence.

Oslo, 17 September 2025: Reference is made to the stock exchange announcement published by BerGenBio ASA (the “Company”) on 5 August 2025 regarding updated key information relating to the contemplated fully underwritten rights issue in the Company raising gross proceeds of NOK 130 million (the “Rights Issue”). Reference is also made to the stock exchange announcement made by the Company earlier today on 17 September 2025, with updated information regarding the timeline for the Rights Issue and the contemplated combination of the Company, Oncoinvent and BerGenBio Norge AS through a statutory triangular merger (the “Merger”). Updated key information relating to the Rights Issue is set out below.

Oslo, 17 September 2025: Reference is made to the joint stock exchange announcement made on 30 June 2025 by BerGenBio ASA (the “Company”) and Oncoinvent ASA (“Oncoinvent”) regarding the contemplated combination of the Company, Oncoinvent and BerGenBio Norge AS through a statutory triangular merger (the “Merger”). Reference is also made to the stock exchange announcement made by the Company on 30 June 2025 regarding a fully underwritten rights issue (the “Rights Issue”) with preferential subscription rights (the “Subscription Rights”) for the Company’s existing shareholders at the time of completion of the Merger (the “Rights Issue Announcement”).